A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens-Reference-Cited by-同舟云学术

A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens

Published:2018-03-01 Issue:5 Volume:14 Page:e231-e237
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Kikuchi Yasuko¹^ORCID,Uchida Yoshihiro²,Shirakawa Kazuo³,Kanauchi Hajime⁴,Niwa Takayoshi¹,Nishioka Kotoe¹,Tada Keiichirou¹,Hashimoto Masanori⁵,Yasuda Hidemitsu⁵,Sugiura Ryoko⁵,Kawabata Hidetaka⁶,Seto Yasuyuki¹,Ogawa Toshihisa⁷

Affiliation:

1. Department of Breast and Endocrine Surgery; Graduate School of Medicine; The University of Tokyo; Tokyo Japan

2. International University of Health and Welfare Mita Hospital Breast Center; Tokyo Japan

3. Josai Hospital; Ibaraki Japan

4. Breast and Endocrine Surgery Department; Showa General Hospital; Tokyo Japan

5. National Center for Global Health and Medicine; Tokyo Japan

6. Breast and Endocrine Surgery; Toranomon Hospital; Tokyo Japan

7. Breast Center; Dokkyo Medical University Koshigaya Hospital; Saitama Japan

Funder

Eisai

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12863/fullpdf

Reference25 articles.

1. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance;Inoue;Breast Cancer Res Treat.,2016

2. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy;Pivot;Ann Oncol.,2016

3. A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer;Takashima;SpringerPlus,2016

4. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes;Maeda;Breast,2017

5. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomized study;Cortes;Lancet,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes;Cancer Medicine;2024-05

2. Eribulin in Metastatic Breast Cancer: Actual Clinical Practice;Creative surgery and oncology;2023-04-05

3. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach;Cancer Chemotherapy and Pharmacology;2022-01-08

4. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2021-07

5. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting;Investigational New Drugs;2020-01-16